Comparison of serum amylase level between dipeptidyl peptidase-4 inhibitor and GLP-1 analog administration in patients with type 2 diabetes mellitus

We monitored serum amylase level in patients with type 2 diabetes mellitus (T2DM) prescribed either dipeptidyl peptidase-4 inhibitor or GLP-1 analog (GLP-1 group) as monotherapy. Patients were treated for a 36-month period. All subjects were non-smoker and did not take any alcoholic beverages. Forty...

Descripción completa

Detalles Bibliográficos
Autores principales: Okada, Junichi, Yamada, Eijiro, Niijima, Yawara, Okada, Shuichi, Yamada, Masanobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854662/
https://www.ncbi.nlm.nih.gov/pubmed/31727181
http://dx.doi.org/10.1186/s41043-019-0197-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854662/
https://www.ncbi.nlm.nih.gov/pubmed/31727181
http://dx.doi.org/10.1186/s41043-019-0197-x

Ejemplares similares